Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PULM = Price $1.70--NEW MEGA CORONA GEM .. New GEM in the Corona area which is dirt cheap at $33 M valaution and around $23 M in Cash
PULM --Market Cap $33 M---Cash $23 M
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19---April 16, 2020
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM = Price $1.70--NEW MEGA CORONA GEM .. New GEM in the Corona area which is dirt cheap at $33 M valaution and around $23 M in Cash
PULM --Market Cap $33 M---Cash $23 M
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19---April 16, 2020
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM = Price $1.70--NEW MEGA CORONA GEM .. New GEM in the Corona area which is dirt cheap at $33 M valaution and around $23 M in Cash
PULM --Market Cap $33 M---Cash $23 M
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19---April 16, 2020
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM = Price $1.80--NEW MEGA CORONA GEM .. New GEM in the Corona area which is dirt cheap at $33 M valaution and around $23 M in Cash
PULM --Market Cap $33 M---Cash $23 M
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19---April 16, 2020
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM = Price $1.80--NEW MEGA CORONA GEM .. New GEM in the Corona area which is dirt cheap at $33 M valaution and around $23 M in Cash
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
ADMP =Price 0.40-CORONA gem close to major breakout
ADMP =MCap $23 M-HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
ADMP = Corona gem could start running toward $1++
ADMP =MC $23 M--HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
ADMP =MC $23 M-HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
ADMP =MC $23 M HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
ADMP =MC $23 M HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
ADMP =MC $23 M HOT CORONA STOCK.. MASSIVE upside here on this unknown corona gem
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-production-products-130010536.html
BREAKING: Egon von Greyerz Just Warned Swiss Refiners Have Halted Gold Production!
https://kingworldnews.com/breaking-egon-von-greyerz-just-warned-swiss-gold-refiners-have-ceased-production/
The section above was written before the news that Swiss refiners are closing production. We must remember that 70% of all gold bars are produced in Switzerland and that the 3 biggest refiners are in Ticino where the local government has ordered non-essential factories to close.
The likely outcome of gold production stopping should be a much higher gold price on Monday. But we obviously don’t know if the BIS and the bullion banks will hit the gold market with $ billions of paper gold. Whatever they do in the short run, the market will soon discover that all this paper gold is worthless.
The gold mining stocks are also likely to suffer until the situation is clarified since they have lost their biggest buyers.
What about the $280 million debt ??
IGXT =Price:0.30-FDA DECISION on March 26 (Migraine Drug) /Market Cap $33 M--CHEAPEST FDA GEM =500% GEM
IGXT =Price:0.30-FDA DECISION on March 26 (Migraine Drug) /Market Cap $33 M--CHEAPEST FDA GEM =500% GEM
NDRA =MC $8 M--O/S 8 M-- MEGA News out today a sleeping giant here
ENDRA Life Sciences Receives CE Mark for its TAEUS(R) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease
https://finance.yahoo.com/news/endra-life-sciences-receives-ce-120000654.html
NDRA =MC $9 M -MONSTER NEWS OUT --Product approved targeting MULTI BILLION $ Market --Undiscovered low float rocket here
Endra Life Science (NDRA)
Market Cap: $9 M
Shares Out: 8.4 M
ENDRA Life Sciences Receives CE Mark for its TAEUS(R) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease...March 10, 2020
https://finance.yahoo.com/news/endra-life-sciences-receives-ce-120000654.html
NDRA =MC $9 M -MONSTER NEWS OUT --Product targeting MULTI BILLION $ Market --Undiscovered low float rocket here
Endra Life Science (NDRA)
Market Cap: $9 M
SHares Out: 8.4 M
ENDRA Life Sciences Receives CE Mark for its TAEUS(R) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease...March 10, 2020
https://finance.yahoo.com/news/endra-life-sciences-receives-ce-120000654.html
IGXT =Price 0.40--FDA DECISION in 20 days
IGXT =Price: 0.40--MC $41 M--FDA DECISION on March 26 (thin-film Migraine Drug) /CHEAPEST FDA GEM for this month ...Could run to $1 even before PDUFA date and with approval a big jump toward $2 is likely .GL
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in 1H-2020
IGXT =Price 0.40--FDA DECISION in 20 days
IGXT =Price: 0.40--MC $41 M--FDA DECISION on March 26 (thin-film Migraine Drug) /CHEAPEST FDA GEM for this month ...Could run to $1 even before PDUFA date and with approval a big jump toward $2 is likely .GL
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in 1H-2020
LPCN =MC $28 M--Cash $20 M --PDUFA Date on August 28 for Tlando (Oral Testosterone) -Additional 2 Drugs ready for Phase 3 trial -- And the NASH program in Phase 2 with results expected in mid 2020 = This stock is a MEGA GIFT at this ridiculous low price ,with FDA approval this stock can hit $10 and much more especially with positive results from their NASH program which is a potential Blockbuster .STRONG BUY and GL
Presentation
http://ir.lipocine.com/download/Exhibit+99.1+Corporate+Presentation+011320.pdf
LPCN =MC $28 M--Cash $20 M --PDUFA Date on August 28 for Tlando (Oral Testosterone) -Additional 2 Drugs ready for Phase 3 trial -- And the NASH program in Phase 2 with results expected in mid 2020 = This stock is a MEGA GIFT at this ridiculous low price ,with FDA approval this stock can hit $10 and much more especially with positive results from their NASH program which is a potential Blockbuster .STRONG BUY and GL
Presentation
http://ir.lipocine.com/download/Exhibit+99.1+Corporate+Presentation+011320.pdf
IGXT =Price: 0.40--FDA DECISION on March 26 (Migraine Drug) /CHEAPEST FDA GEM =500% GEM
Intelgenx (IGXT)
MarketCap $40 million
Cash: $9 million
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IGXT =Price: 0.40--FDA DECISION on March 26 (Migraine Drug) /CHEAPEST FDA GEM =500% GEM
Intelgenx (IGXT)
Market Cap$ 42 million
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
The Fascinating Story of IntelGenx Technologies Corp. (OTCMKTS: IGXT)
https://microcapdaily.com/the-fascinating-story-of-intelgenx-technologies-corp-otcmkts-igxt/124954/
IGXT =Price:0.40--MC $39 M--FDA DECISION on March 26 (Migraine Drug) /CHEAPEST FDA GEM =500% GEM
http://s2.q4cdn.com/790425727/files/images/pipline/2019/Picture1.jpg
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IGXT =MC $39 M--FDA DECISION on March 26 (Migraine Drug) --Price 0.40---CHEAPEST FDA GEM ..Could hit $1 in the coming days
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IGXT =MC $39 M--FDA DECISION on March 26 (Migraine Drug) /CHEAPEST FDA GEM ..Could hit $1 in the coming days
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IGXT =MC $39 M--FDA DECISION on March 26 (Migraine Drug) /CHEAPEST FDA GEM ..Could hit $1 in the coming days
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
MATN =Price 0.26 --Mcap $18 M -UNKNOWN CORONA gem ..likely to $1 in the coming days .Its definitely the CHEAPESTand most attractive of all CORONAS
CHEAPEST CORONA GEMMMMMM RALLLYYYYYYYYYYYYYYy
(MATN-DD) Market Cap $17 M --2x Phase 3 ready programs in Cancer / HOT Corona Gem = THE CHEAPEST and MOST attractive CORONA gem .Company is even corona very attractive = Could run to $2++ easily as long as the virus is out there .STRONG BUY SUPER AGGRESSIVE
Market Cap :$17 Million
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19
https://finance.yahoo.com/news/mateon-provides-rapid-antiviral-response-125010377.html
HUGE Pipeline
http://oncotelic.com/wp-content/uploads/Pipeline05032019.jpg
Presentation
http://oncotelic.com/wp-content/uploads/BIO2019-6-1-2019-BIO-Final-for-upload.pdf
Top Sharesholders:
Trieu (Vuong) ...19.9M
Hwang (Larn Ph.D.) ...4.1M
Hsiao (Chao) ...3.0M
Park (Chulho Ph.D.) ...2.8M
Sabby ...1.7M
Uckun (Fatih ...1.5M
Schwieterman ...625.7K
Loar (Matthew M) ...300.0K
Reynolds (Donald ...280.0K
BlackRock ...11.2K
MATN = price 0.22 CORONA LIFETIME OPP ..market cap a joke at $18 million for a company which has 2 Phase 3 cancer programs ready
MATN =Price 0.23 CORONA BOOOOOOOOOOOOOOOOOOOOOOM
MATN =MC $16 M-NEW HOT CORONA PLAY --DIRT cheap and unknown stock with a MONSTER product pipeline includes to Phase 3 ready programs so its super attractive even without Corona . LOAD UP before she runs like TOMZ or IBIO dit .GL
Mateon Therapeutics (MATN)
Market Cap only $16 million
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19...March 2, 2020
https://finance.yahoo.com/news/mateon-provides-rapid-antiviral-response-125010377.html
Presentation
http://oncotelic.com/wp-content/uploads/BIO2019-6-1-2019-BIO-Final-for-upload.pdf
Top Sharesholders:
Trieu (Vuong) ...19.9M
Hwang (Larn Ph.D.) ...4.1M
Hsiao (Chao) ...3.0M
Park (Chulho Ph.D.) ...2.8M
Sabby ...1.7M
Uckun (Fatih ...1.5M
Schwieterman ...625.7K
Loar (Matthew M) ...300.0K
Reynolds (Donald ...280.0K
BlackRock ...11.2K
MATN =MC $16 M-NEW HOT CORONA PLAY --DIRT cheap and unknown stock with a MONSTER product pipeline so its super attractive even without Corona . LOAD UP before she runs like TOMZ or IBIO dit :GL
Mateon Therapeutics (MATN)
Market Cap only $16 million
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19...March 2, 2020
https://finance.yahoo.com/news/mateon-provides-rapid-antiviral-response-125010377.html
Presentation
http://oncotelic.com/wp-content/uploads/BIO2019-6-1-2019-BIO-Final-for-upload.pdf
Top Sharesholders:
Trieu (Vuong) ...19.9M
Hwang (Larn Ph.D.) ...4.1M
Hsiao (Chao) ...3.0M
Park (Chulho Ph.D.) ...2.8M
Sabby ...1.7M
Uckun (Fatih ...1.5M
Schwieterman ...625.7K
Loar (Matthew M) ...300.0K
Reynolds (Donald ...280.0K
BlackRock ...11.2K
CTX.TO =MC $13 M /PROFITABLE Pharma with many marketed products and a strong pipeline ..Undiscovered company with BRUTAL upside potential
Prsentation
http://www.crescitatherapeutics.com/wp-content/uploads/2019/11/Investor-Presentation-Nov-2019a.pdf
"Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis"
https://www.prnewswire.com/news-releases/crescita-announces-positive-topline-results-from-two-pivotal-phase-3-clinical-studies-for-its-lead-pipeline-product-in-patients-with-plaque-psoriasis-301002807.html
Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita owns a portfolio of non-prescription skincare products and has one FDA approved prescription product, Pliaglis that is licensed globally to Galderma SA and Taro Pharmaceuticals for the U.S. market. Crescita owns the sales and marketing rights in Canada and Mexico.